Celltrion's strategy focuses on developing and manufacturing biosimilars, which are generic versions of biologic drugs. Its current flagship drugs include biosimilars to Remicade, Rituxan ...

We are initiating coverage of biosimilar manufacturer Celltrion. Its current flagship drugs include biosimilars to Remicade, Rituxan, Herceptin, and Avastin. The bottom line: We initiate with a ...

Park Min-ji's competition. The last winner is Lee Ga-young. Park Min-ji's fifth consecutive victory in a single tournament ...

Celltrion, which completed its merger with Celltrion Healthcare in December last year, had been set to merge with Celltrion Pharm, the drugmaker’s domestic distributor and chemical drug development ...

Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers ...

Celltrion has finally merged with Celltrion Healthcare, three years after its original plan was announced. Celltrion announced that its board had approved the merger on Thursday. Each share of ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was ...

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

March 20 (Reuters) - U.S. scientific instruments maker Thermo Fisher Scientific Inc (TMO.N), opens new tab and South Korea's Celltrion Inc (068270.KS), opens new tab are among those competing to ...

TORONTO, March 27, 2025--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry ...

"5 consecutive losses, it wasn't easy. Four consecutive losses are also a record from heaven." There was no reversal. Park ...